DNA helix abstract graphic

    Nasdaq Healthcare & Biotech Listings

    Largest leader of biotech and healthcare IPOs.

    Nasdaq is overwhelmingly the destination for new biotech and healthcare IPOs. As a driver in innovation and R&D, we want to support your company's forward momentum and new plateaus of discovery.

    Lead the Possible

    With disruption in our DNA, we’ve backed biotech companies for 50 years and counting – and we are proud to continue to walk beside them on the journey to a better tomorrow.

    People Icon

    Our Global Community of Healthcare Leaders

    Nasdaq is proud to be a partner to a global community of healthcare leaders, including 98% of U.S. listed biotech companies. Our listed clients choose Nasdaq for our index inclusion opportunities, marketing and visibility platform, and continued public policy advocacy work on behalf our of issuer community.

    990 healthcare corporate clients and over 540 biotech/pharma companies use our in-house shareholder engagement and intelligence tools and governance solutions.

     

    Nasdaq is proud to be a partner to a global community of healthcare leaders, including 98% of U.S. listed biotech companies. Our listed clients choose Nasdaq for our index inclusion opportunities, marketing and visibility platform, and continued public policy advocacy work on behalf our of issuer community.

    990 healthcare corporate clients and over 540 biotech/pharma companies use our in-house shareholder engagement and intelligence tools and governance solutions.

     

    Nasdaq Governance Solutions for Hospital Systems

    Our Index Inclusion Opportunities and Unique Visibility Assets

    Nasdaq has a thriving index business for listed companies to gain exposure to passive investors, which includes the Nasdaq Biotechnology Index (NBI), a market capitalization weighted index focused specifically on the biopharmaceutical industry.

    Nasdaq leads with 100% Biotech IPO win rate

    Nasdaq continues to welcome leading Biotech-Pharma companies such as BrightSpring Health Services, GC Oncology Inc., and ArriVent BioPharma Inc. Five IPOs in the sector raised $1.2 billion in 2024.

    List on Nasdaq ->

    Largest Biopharma IPOs in 2024

    BrightSpring Health Series

    Nasdaq-listed: BSTG
    Raise: $692.9M USD

    Nasdaq-listed: BSTG
    Raise: $692.9M USD

    CG Oncology

    Nasdaq-listed: CGON
    Raise: $380M USD

    Nasdaq-listed: CGON
    Raise: $380M USD

    ArriVent BioPharma

    Nasdaq-listed: AVBP
    Raise: $175M USD

    Nasdaq-listed: AVBP
    Raise: $175M USD

    Jordan Saxe

    We are the home to Biotech because we committed to the industry from the very beginning. Our gateway to the capital markets allows researchers, scientists and business leaders to pioneer the possible every day — and we are proud to be with them at every step of that journey.

    Videos

    Breakthrough Economy

    The Strategy for Excess Capital
    Petri Niemisvirta, CEO of Mandatum plc, joins Jill Malandrino on Nasdaq TradeTalks to discuss structural changes and the strategy for excess capital.
    Mar 25, 2024
    1 / 18

    Recent BioTech Headlines

    Info icon

    This data feed is not available at this time.

    Contact Us

    Get in Touch

    Need support? For questions, please contact:

    People Icon

    Jordan Saxe

    Head of Healthcare Listings
    Jordan.Saxe@nasdaq.com
    +1 212 401 8719

    People Icon

    Carsten Borring

    Healthcare Listings - Nordic Market
    Carsten.borring@nasdaq.com
    +45 40707194

    People Icon

    Peter Legind-Hansen

    Healthcare Listings - Nordic Market
    peter.legind-hansen@nasdaq.com
    +45 40727195

    Nasdaq Listing Applications

    Value icon

    Nasdaq Symbol Reservation

    Explore listing potential

    Learn more about biotech and healthcare listings on Nasdaq.